ホーム > 医療関係者の皆さま > 着用型自動除細動器 LifeVest > 関連文献

着用型自動除細動器 LifeVest

関連文献

参考文献
着用型自動除細動器に関する文献をご紹介します。


  1. Duncker et al., “Wearable cardioverter/defibrillator in peripartum cardiomyopathy early after diagnosis - a multicenter study,” Presented at DGK Spring 2015 [in German].

  2. Johnson et al. “Arrhythmia treatment and survival of Patients wearing the LifeVest,” Presented at DGK Spring 2015 [in German].

  3. Schmitt et al. “ICD-implantation, ICD-treatment and general survival of patients after returning the LifeVest,” Presented at DGK Spring 2015 [in German].

  4. Lang et al. “Wearable Cardioverter/Defibrillator (WCD) zur Risikostratifizierung und Uberbruckung transienter Phasen mit einem hohen Risiko fur den plotzlichen Herztod,”

  5. Sanders et al., “Potential Cost-effectiveness of Wearable Cardioverter Defibrillator Early Post Myocardial Infarction,” J Innovations in Cardiac Rhythm Management, 2015; 6(2015): 1929-1940.

  6. Healy et al., “Wearable Cardioverter Defibrillator for Prevention of Sudden Cardiac Death Following Infected Implantable Cardioverter Defibrillator Removal: A Cost-Effectiveness Evaluation,” Heart Rhythm. 2015; Mar 31. [Epub ahead of print].

  7. Huang et al., “Wearable cardioverter-defibrillator use in patients after myocardial infarction,” Zhonghua Xin Xue Guan Bing Za Zhi. 2014; 42(8):703-5. In Chinese.

  8. Duncker et al, “Risk for Ventricular Fibrillation in Peripartum Cardiomyopathy with Severely Reduced Left Ventricular Function – Value of the Wearable Cardioverter Defibrillator,” Eur J Heart Fail 2014 16(12):1331-6.

  9. Sasaki, et al.” Usefulness of the WCD in Patients at High Risk for Sudden Cardiac Death,” Circulation Journal 2014 78(12):2987-9.

  10. Perumal, et al. “WCD Treatment Characteristics and Outcomes in Recent Myocardial Infarction Patients with Heart Failure,” Circulation 2014; 130:A16255

  11. Wan, et al. “Left Ventricular Function Improvement After Recent MI in Patients Using a Wearable Cardioverter Defibrillator,” Circulation 2014; 130:118973

  12. Bianco, et al. “Life-Threatening Arrhythmias During Wearable Cardioverter Defibrillator Use” Circulation 2014; 130:A16751

  13. Wan, et al. “The Wearable Cardioverter Defibrillator Protects Older Patients from Sudden Cardiac Death” Circulation 2014; 130:A341

  14. Chung MK, “The role of the wearable cardioverter defibrillator in clinical practice,” Cardiol Clin, 2014 May;32(2):253-70.

  15. Tanawuttiwat et al., “Protection from outpatient sudden cardiac death following ICD removal using a wearable cardioverter defibrillator,” PACE, 2014 May;37(5):562-8.

  16. Fan et al., “Application of ICD guidelines and indications in a community-based academic hospital: a case series-based discussion,” J Community Hosp Intern Med Perspect, 2014 Apr 14;4.

  17. Owen et al., “Personal Wearable Defibrillators for adults with long QT syndrome,” Heart Rhythm, 2014; 11(5):S52-S53.

  18. Duncker et al., “Risk of ventricular fibrillation in young mothers with peripartum cardiomyopathy,” Heart Rhythm, 2014; 11(5):S391.

  19. Bianco et al., “Wearable Cardioverter Defibrillator Use for Short-Term SCA Protection in Patients with Preserved LVEF Heart Failure,” Eur J Heart Fail, 2014; 16(s2):51.

  20. Wan et al., “Use of the Wearable Cardioverter Defibrillator in Patients with Infiltrative Disorders,” Eur J Heart Fail, 2014; 16(s2):314.

  21. Sinha et al., “Wearable Cardioverter Defibrillator in Patients with High Risk for Life-Threatening Cardiac Arrhythmias,” Europace, 2014; 16(suppl 2):ii96.

  22. Bianco et al., “Long-Term Use of the Wearable Cardioverter Defibrillator in ICD Explant Patients,” Europace, 2014; 16(suppl 2):ii97.

  23. Mijic et al., “The Wearable Cardioverter Defibrillator (WCD): A Sparkling Light in the Temporary Black Box before ICD Implantation,” Europace, 2014; 16(suppl 2):ii97.

  24. Permual et al., “Circadian variation of ventricular arrhythmias does not affect survival in patients using the wearable cardioverter defibrillator,” Euro Heart J, 2014; 35 (suppl 1):530.

  25. Wan et al., “Bridging to Recovery: Experience with the Wearable Cardioverter Defibrillator in Patients with Tachycardia-Induced Cardiomyopathy,” J of Cardiac Fail, 2014; 20 (8):S88-S89.

  26. Salehi et al, “Experience with Wearable Cardioverter-Defibrillator in Non-ischemic Cardiomyopathy: a National Database Analysis,” J Am Coll Cardiol, November 2, 63:12S.

  27. Bianco et al, “Survivors of Sudden Cardiac Arrest in the Presence of myocardial Infarction: Secondary Prevention with the Wearable Cardioverter Defibrillator,” J Am Coll Cardiol, 2014, 63:12S.

  28. Wickenbrock et al, “Ventricular tachycardia in post-infarction patients and coronary heart disease: treatment and prognostic significance,” Herzschr Elektrophys, 2014, 25:47-52. (in German).

  29. Bowers et al, “Use of external defibrillator jacket to facilitate safe delivery of radiotherapy for lung cancer - A report of two cases,” Indian Heart J . 2014, Jan-Feb, 66(1):111-4.

  30. Frances et al, “Wearable cardioverter defibrillator: A life vest till the lifeboat (ICD) arrives,” Indian Heart J . 2014, 2014, 66:68-72.

  31. Stollberger et al, “Wearable Cardioverter-Defibrillator in a Patient with Left Ventricular Noncompaction/Hypertrabeculation, Coronary Artery Disease, and Polyneuropathy,” Ann Noninvasive Electrocardiol, 2014, 00(0):1-3.

  32. Liang et al, “Temporal Evolution and Implications of Ventricular Arrhythmias Associated with Acute Myocardial Infarction,” Cardiol Review, 2013, 21:289-294.

  33. Wan et al, “Sudden Cardiac Arrest in Hemodialysis Patients with Wearable Cardioverter Defibrillator,” Ann Noninvasive Electrocardiol. 2013, November 2, [Epub ahead of print].

  34. Wan et al, “Successful use of wearable cardioverter defibrillator in a patient with dextrocardia and persistent left superior vena cava,” Ann Noninvasive Electrocardiol, 2013, Epub 2013 May 3, Sep;18(5):487-90.

  35. Nascimento et al, “Wearable cardioverter defibrillator in stress cardiomyopathy and cardiac arrest,” BMJ Case Rep, September 2013.

  36. Möller et al, “Pacemaker dependent and/or repetitive ICD therapies. How to solve the dilemma of lead extraction?,” Herzschrittmacherther Elektrophysiol, 2013, 24(3):152-7. (in German).

  37. Wan et al, “The impact of body mass index on wearable cardioverter defibrillator efficacy,” Euro Heart J, 2013, 34(suppl 1): S903.

  38. Bianco et al, “Utility of wearable cardioverter defibrillators in European patients early after myocardial infarction,” Euro Heart J, 2013, 34(suppl 1): S244.

  39. Epstein et al, “Wearable Cardioverter-Defibrillator Use in Patients Perceived to be at High Risk Early Post Myocardial Infarction,” J Am Coll Cardiol, 2013 Jul 20, [Epub ahead of print].

  40. Strauss et al, “A patient with severely reduced LV function and electrical storm saved by wearable cardioverter-defibrillator: a case report,” Herzschrittmacherther Elektrophysiol, 2013, 24(2):136-8.

  41. Bianco et al, “Compliance with wearable cardioverter-defibrillator use in a European cohort of patients,” Europace, 2013, 15(suppl 2):ii260.

  42. Wan et al, “Risk of sudden cardiac arrest in patients with myocarditis and the use of wearable cardioverter defibrillator: a German experience,” Europace, 2013, 15(suppl 2):ii117.

  43. Klein et al, “Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator,” Eur Heart J, 2013, 34(29):2230-42. Epub 2013 May 31.

  44. Bianco et al, “Wearable Cardioverter Defibrillator Use in Patients with Chemotherapy-Induced Cardiotoxicity,” Eur J Heart Fail, 2013, 12(suppl 1):S324.

  45. Shin et al, “Lifesaving events in patients protected by a wearable cardioverter-defibrillator: A single center experience,” DGK, 2013.

  46. Sperzek et al, “Role Of The Defibrillator Vest As Bridging Therapy Before ICD (Implantable Cardioverter/Defibrillator) Implantation,” Heart Rhythm, 2013, 10(5):S72.

  47. Floor et al, “The use of Wearable Cardioverter Defibrillator among high risk cardiac patients,” Heart Rhythm, 2013, 10(5):S105.

  48. Floor et al, “The use of Wearable Cardioverter Defibrillator among high risk cardiac patients,” Heart Rhythm, 2013, 10(5):S105.

  49. Styperek, R., “Preventing Sudden Cardiac Death Following Coronary Artery Bypass Graft,” EP Lab Digest, August 2013, 16-18.

  50. Goldenberg et al, “Eighteen Month Results From The Prospective Registry And Follow-up Of Patients Using The Lifevest Wearable Defibrillator (WEARIT-II Registry),” Heart Rhythm Society, 2013, Late Breaking Clinical Trial. View Presentation recorded at HRS 2013

  51. Deeprasertkul et al, “National Experience with Wearable Cardioverter-Defibrillator Use in Takotsubo Cardiomyopathy,” Journal of the American College of Cardiology, 2013, 61 (S10).

  52. Adler et al, “Wearable cardioverter-defibrillators,” Circulation, 2013, 127(7):854-60.

  53. Norman and Collier, “A Collaborative Approach to Managing Sudden Cardiac Death Risk,” Diagnostic and Interventional Cardiology, March/April 2013, 24-25.

  54. Zishiri et al, “Early Risk of Mortality after Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction and Potential Role of the Wearable Cardioverter Defibrillator,” Circulation: Arrhythmia and Electrophysiology, February 2013, 117-128.

  55. Kao et al, “Wearable defibrillator use in heart failure (WIF): results of a prospective registry,” BioMed Central Cardiovascular Disorders, 2012, 12(1):123.

  56. Karia et al, “Baseline ECG Predictors of 90-Day Survival in Wearable Cardioverter-Defibrillator Patients Experiencing a Sudden Cardiac Arrest,” Circulation, 2012, 126:A186.

  57. Karia et al, “Dynamic ECG Changes in Wearable Cardioverter Defibrillator Patients Predict Impending Sudden Cardiac Arrest,” Circulation, 2012, 126:A8.

  58. Wan et al, “Patients with Terminal Illness Using a Wearable Cardioverter Defibrillator,” Circulation, 2012, 126:A75.

  59. Horstmanshof et al, “Experience with the Wearable Cardioverter Defibrillator in Heart Transplant Candidates,” Journal of Cardiac Failure, 2012, 18(10 suppl):S49-S50.

  60. Wan et al, “Use of Wearable Cardioverter Defibrillator after Implantable Cardioverter Defibrillator explantation: Clinical Experience from 151 German centers,” European Heart Journal, 2012, 33(suppl 1):Sxxx.

  61. Wan et al, “Physical Activity and Relation to Sudden Cardiac Arrest,” Europace, 2012, 14(suppl 1):i122.

  62. Levine, J., “Sudden Cardiac Arrest in a Young AMI Patient Following Percutaneous Revascularization,” CardioSource Interventional News, July/August 2012, 18-20.

  63. Goodfellow, R., “Preventing Sudden Cardiac Death Following Percutaneous Revascularization,” Cath Lab Digest, June 2012, 16-18.

  64. Szymkiewicz et al, “ECG Quality of Dry, Non-adhesive Electrodes for Arrhythmia Monitoring [Abstract],” Europace, 2012, 14(suppl 1):i1.

  65. Wan et al, “Physical Activity and Relation to Sudden Cardiac Arrest [Abstract],” Europace, 2012, 14(suppl 1):i122.

  66. Bianco et al, “Protecting the Alcoholic Cardiomyopathy Patient: Bridge to Decision with the Wearable Cardioverter Defibrillator [Abstract],” European Journal of Heart Failure, 2012, 11(suppl 1):S21.

  67. Glad et al, “Do multiple shock episodes impact survival outcomes in patients with a Wearable Cardioverter Defibrillator? [Abstract],” Heart Rhythm, 2012, 9(5):S446.

  68. Peters et al, “WCD LifeVest: risk stratification in a case of Tako-Tsubo cardiomyopathy with QT interval prolongation,” Herz, 2012, 37(2):219-21.

  69. Whiting, J., Simon, M., “Health and Lifestyle Benefits Resulting from Wearable Cardioverter Defibrillator Use,” The Journal of Innovations in Cardiac Rhythm Management, March 2012, 1-2.

  70. Epstein et al, “Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-MI [Abstract],” Journal of the American College of Cardiology, 2012, 59:E644.

  71. Wan et al, “Improved sudden cardiac arrest survival in hemodialysis patients with wearable cardioverter-defibrillator [Abstract],” Journal of the American College of Cardiology, 2012, 59:E651.

  72. Mirro, M., “Use of the Wearable Automatic Defibrillator: Outcomes and Compliance [Abstract],” Heart Rhythm, 2011, 8 (S5):S435.

  73. Knops et al, “First experience with the wearable cardioverter defibrillator in the Netherlands,” Netherlands Heart Journal, 2012, 20(2):77-81.

  74. Saltzberg et al, “Characteristics and Outcomes of Peripartum versus Non-peripartum Cardiomyopathy in Women using a Wearable Cardiac Defibrillator,” Journal of Cardiac Failure, 2012, 18:21-27.

  75. Zishiri et al, “Use of the Wearable Cardioverter Defibrillator and Survival After Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction [Abstract],” Circulation, 2011, 124:A9816.

  76. Cronin et al, “Some Like It Cool - Seasonal Temperature, as Well as Clinical And Demographic Factors, Predicts Compliance With the Wearable Cardioverter Defibrillator [Abstract],” Circulation, 2011, 124:A14183.

  77. Mosesso et al, “Successful conversion of Ventricular arrhythmias by a Wearable Defibrillator [Abstract],” Circulation, 2011, 124:A278.

  78. Wan et al, “Economic Evaluation of the Wearable Cardioverter-Defibrillator in Patients After ICD Explantation [Abstract],” Circulation, 2011, 124:A245.

  79. Wan et al, “The Wearable Cardioverter Defibrillator Is Cost-Effective in Protecting High-Risk Patients After Acute Myocardial Infarction [Abstract],” Circulation, 2011, 124:A100.

  80. Dewland et al, “Indications for Wearable Cardioverter Defibrillator,” Cardiac Electrophysiology Clinics, 2011, 3(2001), 339-347.

  81. Austin et al, “Frequency of Improvement in Ventricular Function Allows Many Patients to Defer Defibrillator Implantation,” Journal of Cardiac Failure, 2011, 17(8): S102.

  82. Bianco et al, “Extending Wearable Cardiac Defibrillator Use in Heart Failure Patients beyond the ICD waiting period,” Journal of Cardiac Failure, 2011, 17(8): S52.

  83. Everitt et al, “The Wearable External Cardiac Defibrillator for cancer patients at risk for sudden cardiac death,” Community Oncology, 2011, 8(9): 400-403.

  84. Mohan Rao et al, “Wearable defibrillator in Congenital Structural Heart Disease and Inherited Arrhythmias: A Multicenter Experience,” Journal of Cardiovascular Electrophysiology, 2011, In press.

  85. Saltzberg et al, “Characteristics and Outcomes of Peripartum versus Non-peripartum Cardiomyopathy in Women using a Wearable Cardiac Defibrillator,” Journal of Cardiac Failure, 2011, In press.

  86. Glad et al, “Protecting Tako tsubo patients from sudden death: Are wearable defibrillators the answer,” Journal of Cardiac Failure, Vol 17, Issue 8, Supplement 1, Page S55.

  87. Wan et al, “Incidence of Inappropriate Wearable Defibrillator Shocks is Rare: An Evaluation fo 15,193 Wearable Defibrillator Patients,” Europace, 2011, 13(3): 375.

  88. Saltzberg et al, “Use of a Wearable Cardioverter Defibrillator among Pre-partum Pregnant Women: An analysis of Safety, Characteristics and Outcomes,” European Journal of Heart Failure, 2011, 10(suppl 1):S26.

  89. Karia et al, “Rate of LV Systolic Function Recovery in Cardiomyopathy Patients Prescribed Wearable Cardiac Defibrillator,” European Heart Failure Congress, 2011.

  90. Glad et al, “Survival outcomes for post shock asystole in patients wearing a WCD,” Europace, 2011, 13(3): 1203.

  91. Glad et al, “Sudden cardiac arrest survival in patients wearing a wearable cardiac defibrillator: Geographic location does not impact survival,” Europace, 2011, 13(3): 1204.

  92. Bianco et al, “Long-Term Mortality Risk in Post-Myocardial Infarct Patients Resuscitated by a Wearable Cardiac Defibrillator,” Journal of the American College of Cardiology, April 5, 2011, 57: E39.

  93. Carillo, R., “Wearable Defibrillator in Patients Following ICD Explants for Sudden Cardiac Death Protection [Abstract],” Heart Rhythm, 2011, 8(5S): S435.

  94. Hanson, R. et al, “Clinical Outcomes among Patients Using a Wearable Defibrillator,” Journal of the American College of Cardiology, April 5, 2011, 57: E1128.

  95. Rao, M. et al, “Wearable Defibrillator in Congenital Heart Disease and Inherited Arrhythmia: A Multicenter Experience,” Journal of the American College of Cardiology, April 5, 2011, 57: E467.

  96. Deering et al, “Wearable Defibrillator Use After Myocardial Infarction: Results of the WAMI Registry,” JACC, 2011, 57:A14.

  97. Conti, “External Defibrillator, Life Vest Wearable Defibrillator, or Both?,” Clin Cardiol, 2010, 33(12):722-3.

  98. Glad et al, “Early Defibrillation in Patients Wearing a Wearable Defibrillator,” Circulation, 2010, 12(2):120.

  99. Bianco et al, “Wearable Defibrillators Within a NYHA Class IV Heart Failure Population,” Journal of Cardiac Failure, 2010, 16(8):S57.

  100. Verdino, “The Wearable Cardioverter-Defibrillator: Lifesaving Attire or "Fashion Faux Pas?,” JACC, 2010, 56:204-205.

  101. Chung et al, “Aggregate national experience with the wearable cardioverter-defibrillator vest: event rates, compliance and survival,” JACC, 2010, 56:194-203.

  102. Bianco et al, “The Impact of Age on Wearable Cardioverter-Defibrillator Compliance and Treatment,” Europace, 2010, 12(1 suppl):i158.

  103. Bianco et al, “Impact of transthoracic impedance on wearable cardioverter-defibrillator effectiveness,” Europace, 2010, 12(1 suppl):i53.

  104. Karia et al, “Newly Diagnosed Non-ischemic Cardiomyopathy patients bridged with the Wearable Cardioverter Defibrillator,” Eur J Heart Failure, 2010, 9 (suppl 1):S149.

  105. Mitrani et al, “Use of Automatic Wearable Defibrillator in an Uninsured Patient Population,” Heart Rhythm, 2010, 7(5 suppl):S234.

  106. Carrillo et al, “Wearable defibrillator use after ICD explantation,” Heart Rhythm, 2010, 7(5 suppl):S437.

  107. Bianco et al, “Impact of transthoracic impedance on wearable cardioverter-defibrillator effectiveness,” Heart Rhythm, 2010, 7(5 suppl):S365.

  108. Zishiri, et al, “Appropriateness of ICD indications: insights from an analysis of mortality rates in patients using a wearable cardioverter-defibrillator,” Heart Rhythm, 2010, 7(5 suppl):S122.

  109. Szymkiewicz et al, “Wearable defibrillator use prior to ICD implantation or evaluation,” Heart Rhythm, 2010, 7(5 suppl):S54.

  110. Chung et al., “Aggregate national experience with the wearable cardioverter-defibrillator vest: event rates, compliance and survival,” JACC, 2010, 55(10 suppl 1):A10.

  111. Everitt et al., “Use of the Wearable External Cardiac Defibrillator in Children,” PACE, 2010 Feb 23., [Epub ahead of print].

  112. Klein et al., “The Wearable Cardioverter Defibrillator: Bridge to the Implantable Defibrillator,” Cardiac Electrophysiology Clinics, 2009, 2009;1(1):129-46.

  113. Zareba et al., “Sudden Cardiac Arrest in End-Stage Renal Disease: Successful Resuscitation With Wearable Cardiac Defibrillator,” Circulation, Nov 2009, 120: S701 - S702.

  114. Prochnau, “Successful use of a wearable cardioverter-defibrillator in myocarditis with normal ejection fraction,” Clin Res Cardiol, 2009 Nov 17., [Epub ahead of print].

  115. Klein et al., “Bridging a Temporary High Risk of Sudden Arrhythmic Death. Experience with the Wearable Cardioverter Defibrillator (WCD),” PACE, 2009 Nov 2, [Epub ahead of print].

  116. Lee et al., “Role of wearable and automatic external defibrillators in improving survival in patients at risk for sudden cardiac death,” Curr Treat Options Cardiovasc Med, 2009, 11(5):360-5.

  117. Saltzberg et al., “Characteristics of Peripartum Cardiomyopathy Patients Using a Wearable Cardiac Defibrillator,” Journal of Cardiac Failure, 2009, 15(6):S59.

  118. Dillon et al., “An evaluation of the effectiveness of a wearable cardioverter defibrillator detection algorithm,” Journal of Electrocardiology, 2009 June, (electronic ahead of print).

  119. Morrison et al., “Taking a vested interest in a wearable cardioverter defibrillator,” Nursing, 2009, 39(6):30-2.

  120. Szymkiewicz, et al., “Incidence and causes of inappropriate defibrillation during wearable defibrillator use,” Heart Rhythm, 2009, 6(5): S74.

  121. Lewicke et al., “Exploring QT interval changes as a precursor to the onset of ventricular fibrillation/tachycardia,” Journal of Electrocardiology, 2009, 42(4):374-9.

  122. Szymkiewicz, et al., “A Comparison of Compliance and Effectiveness of Wearable Defibrillators and Home AEDs in Out-of-Hospital Sudden Cardiac Arrest,” Circulation, 2008, 118: S_1466.

  123. Mortada et al., ““Sudden Cardiac Death” in: Jeremias A, Brown DL (eds),” Cardiac Intensive Care, 2nd Edition, Elsevier, St. Louis (in press).

  124. Abi-Samra et al., “Wearable Defibrillator: Effective Bridging Substitute for ICD Implants,” Europace, 2008, 10: i160.

  125. Freeman et al., “Is Severe Post-shock Bradyarrhythmia In Patients Using Wearable Defibrillators Common or Serious?,” Circulation, 2007, 116: II_931.

  126. Wang et al., “Ventricular Fibrillation remains the Primary Presenting Rhythm: Results from the Wearable Cardioverter Defibrillator Human Study,” Circulation, 2007, 116: II_934 - II_935.

  127. Choudhuri et al., “Arrhythmic Events During the 40/90 days ‘Cooling Off’ Period: Clinical Utility of the Wearable Defibrillator,” Circulation, 2007, 116: II_348.

  128. Traub et al., “Sudden cardiac arrest aborted by a wearable cardioverter-defibrillator in newly diagnosed non-ischemic cardiomyopathy,” Heart Rhythm, 2007, 4(5, suppl):S101.

  129. Losordo et al., “Intramyocardial Transplantation of Autologous CD34+ Stem Cells for Intractable Angina: A Phase I/IIa Double-Blind, Randomized Controlled Trial,” Circulation, 2007, 115:3165 - 3172.

  130. Gronda et al., “Heart Rhythm Considerations in Heart Transplant Candidates and Considerations for Ventricular Assist Devices: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates?006,” J Heart Lung Transplant, 2006, 25(9):1043-1056.

  131. Szymkiewicz et al., “Analysis of Sudden Cardiac Arrests During Wearable Defibrillator Use,” Circulation, 114 (18, suppl II):II-349, 2006.

  132. Wase, “Wearable Defibrillators: A New Tool in the Management of Ventricular Tachycardia/Ventricular Fibrillation,” EP Lab Digest, 2005, 12:22-24.

  133. Meltendorf, “Using the Wearable Cardioverter Defibrillator a strategy for bridging high risk patients after CABG,” Heart Rhythm, 2005, 2(5, suppl):S32.

  134. Joseph et al., “Compliance and Effectiveness of the Wearable Defibrillator Vest,” JACC, 2004, 43(5, suppl A):300A.

  135. Chung et al., “Robust Long-Term Cardiac Monitoring Using Dry, Non-adhesive Capacitive Electrodes,” JACC, 2004, 43(5, suppl A):141A.

  136. Feldman et al., “Use of a Wearable Defibrillator in Terminating Tachyarrhythmias in Patients at High Risk for Sudden Death: Results of WEARIT/BIROAD,” PACE, 2004, 27:4-9.

  137. Beauregard, “Personal Security: Clinical Applications of the Wearable Defibrillator,” PACE, 2004, 27(1):2-3.

  138. Reek et al., “Clinical Efficacy of a Wearable Defibrillator in Acutely Terminating Episodes of Ventricular Fibrillation Using Biphasic Shocks,” PACE, 2003, 26:2016-2022.

  139. Suzzani P et al., “The lifecor lifevest™ wearable cardioverter defibrillator,” Europace, 2003, 4(Supplement 1):A46.

  140. Pignatelli et al., “Use of a new wearable cardioverter defibrillator to reduce the risk of sudden cardiac death,” Europace, 2003, 4(Supplement 1):A45-A46.

  141. Gasparini et al., “A new wearable defibrillator: Initial single center experience,” Europace, 2003, 4(Supplement 1):A45.

  142. Capucci et al., “Cost-effective use of a new wearable cardioverter defibrillator to protect patients at risk of SCA,” Europace, 2003, 4(Supplement 1):A44-A45.

  143. Reek et al., “Clinical Efficacy of the Wearable Defibrillator in Acutely Terminating Episodes of Ventricular Fibrillation Using Biphasic Shocks,” PACE, 2003, 25(4, part II):577.

  144. Reek et al., “A wearable defibrillator for patients with an intermittent risk of arrhythmia,” Dtsch Med Wochenschr, 2002, 127(41):2127-30.

  145. Schott, “The Wearable Defibrillator,” J Cardiovasc Nurs, 2002, 16(3):44-52.

  146. Reek et al., “The Wearable Cardioverter Defibrillator (WCD®) for the prevention of sudden cardiac death? a single center experience,” Z Kardiol, 2002, 91:1044?052.

  147. Meltendorf et al., “The Wearable Defibrillator? A new Method to prevent Sudden Death,” PACE, 2000, 23(4, part II):606.

  148. Auricchio et al., “Clinical Efficacy of the Wearable Cardioverter-Defibrillator in Acutely Terminating Episodes of Ventricular Fibrillation,” Am J Card, 1998, 81(10):1253-1256.